公开(公告)号：AU2014336929B2

公开(公告)日：2018-11-22

申请号：AU2014336929

申请日：2014-10-17

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  FEHER MIKLOS ,  PAULS HEINZ W

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer. Compound (I)

公开(公告)号：HUE030651T2

公开(公告)日：2017-05-29

申请号：HUE11764988

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

IPC: A61P35/00

公开(公告)号：LT2556071T

公开(公告)日：2017-01-25

申请号：LT11764988

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14

公开(公告)号：SG11201602783SA

公开(公告)日：2016-05-30

申请号：SG11201602783S

申请日：2014-10-17

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  FEHER MIKLOS ,  PAULS HEINZ W

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.

公开(公告)号：CA2889919A1

公开(公告)日：2014-05-22

申请号：CA2889919

申请日：2013-11-15

Applicant: UNIV HEALTH NETWORK

Inventor： LIU YONG ,  PAULS HEINZ W ,  LAUFER RADOSLAW ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  FEHER MIKLOS ,  NG GRACE ,  PATEL NARENDRA KUMAR B ,  LANG YUNHUI

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

公开(公告)号：AU2011238384A1

公开(公告)日：2012-09-27

申请号：AU2011238384

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

IPC: C07D403/04 ,  A61K31/5377 ,  A61P35/00 ,  C07D413/14

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

公开(公告)号：CA2791324A1

公开(公告)日：2011-10-13

申请号：CA2791324

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D403/04

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

公开(公告)号：CA2709536A1

公开(公告)日：2009-07-02

申请号：CA2709536

申请日：2008-12-19

Applicant: UNIV HEALTH NETWORK

Inventor： PAULS HEINZ W ,  FORREST BRYAN T ,  LAUFER RADOSLAW ,  FEHER MIKLOS ,  SAMPSON PETER BRENT ,  PAN GUOHUA ,  LI SZE-WAN ,  LIU YONG

IPC: C07D403/06 ,  A61K31/416 ,  A61K31/4192 ,  A61P35/00 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

公开(公告)号：CA2694724A1

公开(公告)日：2009-02-05

申请号：CA2694724

申请日：2008-08-01

Applicant: UNIV HEALTH NETWORK

Inventor： FEHER MIKLOS ,  FORREST BRYAN T ,  LANG YUNHUI ,  LAUFER RADOSLAW ,  LIU YONG ,  PAN GUOHUA ,  PAULS HEINZ W ,  SAMPSON PETER BRENT ,  YAO YI

IPC: C07D211/58 ,  A61K31/17 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61P3/10 ,  A61P35/00 ,  C07C275/32 ,  C07D205/04 ,  C07D207/50 ,  C07D211/56

Abstract: A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：MX386480B

公开(公告)日：2025-03-18

申请号：MX2018000048

申请日：2018-01-08

Applicant: UNIV HEALTH NETWORK

Inventor： NG GRACE ,  LAUFER RADOSLAW ,  LI SZE-WAN ,  LIU YONG ,  PATEL NARENDRA KUMAR B ,  PAULS HEINZ W ,  SAMPSON PETER BRENT ,  LANG YUNHUI

IPC: C07D495/04 ,  A61K31/4355 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/551 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

Abstract: Se describen compuesto de tienopiridinona de la Fórmula (I) y sus sales farmacéuticamente aceptables; en estos compuestos, uno de X1; X2 y X3 es S y los otros dos son cada uno independientemente CR, en donde R y demás variables son como se define en el presente; los compuestos muestran inhibir la actividad de quinasa HPK1 y tener actividad anti-tumoral in vivo; los compuestos pueden ser eficazmente combinados con portadores farmacéuticamente aceptables y también con otros enfoques inmunomoduladores, tales como la inhibición del punto de control o inhibidores de oxidación de triptófano. (ver Fórmula).